NeuroMab™ Anti-TNFR2 BBB Shuttle Antibody(NRZP-1022-ZP2697)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Human

Applications

ELISA; FC; In Vitro; Inhib; In Vivo; Antagonist

Relevant Diseases

Neuroinflammation

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

TNFR2

Official Name

TNFR2

Full Name

Tumor necrosis factor receptor 2

Alternative Names

TNFRSF1B; CD120b; TBPII; TNF-R-II; TNF-R75; TNFBR; TNFR1B; TNFR2; TNFR80; p75; p75TNFR; tumor necrosis factor receptor superfamily member 1B; TNF receptor superfamily member 1B

Product Pictures

FuncS

Fig.1 showing the results of duplicate experiments conducted in order to determine the effect of TNFRAB2 on T-reg cell proliferation.

LIM1863 xenograft tumor growth curves during treatment with mAb avp6 3G9 (A), soluble TGFbRII-Fc-Ig fusion protein (▼), or vehicle PBS (■).

Inhib

Fig.2 is a graph showing the ability of TNFRAB1 and TNFRAB2 to inhibit the proliferation of T-reg cells generally.

LIM1863 xenograft tumor growth curves during treatment with mAb avp6 3G9 (A), soluble TGFbRII-Fc-Ig fusion protein (▼), or vehicle PBS (■).

FuncS

Fig.3 is a graph showing the effect of TNFRAB1 and TNFRAB2 on T-reg cell proliferation relative to the effect induced by treatment with IL-2.

LIM1863 xenograft tumor growth curves during treatment with mAb avp6 3G9 (A), soluble TGFbRII-Fc-Ig fusion protein (▼), or vehicle PBS (■).

FCM

Fig.4 flow cytometry plots demonstrating the effect of agents that direct the growth of T-reg cells (e.g., TNFα, IL-2, and TNFR2 agonists) as well as a TNFR2 antagonist, TNFRAB2, on the proliferation of T-reg cells of various phenotypes.

Treatment with a TNFR2 antagonist antibody preferentially inhibits the proliferation of CD25Hi-expressing T-reg cells. The proportion of CD4+, CD25Hi+ cells expressing TNFR2 after up to 48 hours of incubation with either IL-2 (200 U/ml) alone, with TNFα (20 ng/ml), or with TNFR2 antagonist antibodies (12.5 pg/ml) is shown.